Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jounce's Immunotherapy Recruiting Coup

This article was originally published in Start Up

Executive Summary

Cancer immunotherapy start-up Jounce Therapeutics scored a major recruiting coup in naming former Merck SVP Richard Murray as its new CEO. At Merck, Murray was integrally involved in advancing Merck's anti-PD-1 program and in ushering pembrolizumab from the lab through to the acceptance of its Biologics License Application filing in just over three years.

You may also be interested in...

Jounce Gets $261m To Start, Milestone Fees Up To $2.3bn In Celgene Deal

A deal with Celgene Corp. worth $261m up front will save Jounce Therapeutics Inc. from having to wade into the treacherous market for initial public offerings in order to advance and accelerate its immuno-oncology research and development programs.

Combo Craze: For PD-1s, Research Alliances Are The Order Of The Day

Pfizer and Merck are the latest to study a new combination in the field of immuno-oncology, but PD-1 frontrunners including Merck, Bristol-Myers Squibb and Roche are already making headway testing multiple drug combinations in pursuit of the most effective and safest way to treat cancer.

Merck Drives Into Immunotherapy “Wild West” With New Trials

Company moves fast to test pembrolizumab in head and neck cancer, among other new frontier tumor types. The firm has reorganized its oncology business to prepare for launch in melanoma, which will be a critical test of the company’s ambitions to become a cancer powerhouse.

Related Content


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts